Ipamorelin

Research Use Only Disclaimer

Ipamorelin is sold strictly for laboratory, academic and institutional research. It is not for human or animal consumption, injection, or any therapeutic, diagnostic or veterinary use. PCH Peptides does not provide dosage, administration or usage guidance.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed in the 1990s as part of research into growth hormone secretagogues and their interactions with specific cellular receptors.

The peptide consists of five amino acid residues arranged in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.

Its structure incorporates non-natural amino acid residues, including alpha-aminoisobutyric acid (Aib), D-2-naphthylalanine and D-phenylalanine.

These structural characteristics contribute to its molecular stability and distinguish it from naturally occurring peptide hormones.

Ipamorelin interacts with the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor targeted by the naturally occurring hormone ghrelin.

Researchers investigate Ipamorelin in controlled laboratory models involving receptor-binding affinity, peptide stability, molecular characterization and growth hormone secretagogue signalling.

Compared with earlier synthetic secretagogues such as GHRP-6 Acetate, Ipamorelin has been investigated for its comparatively selective activity profile in experimental models.

For additional background on peptide classifications and laboratory research applications, explore the list of research peptides.

Ipamorelin 10mg Specifications

Ipamorelin in Laboratory Research

Ipamorelin is investigated in biochemical and cellular models involving ghrelin-receptor interactions, peptide signalling and synthetic secretagogue characterization.

Ghrelin Receptor (GHS-R1a) Binding

The growth hormone secretagogue receptor, GHS-R1a, is a G protein-coupled receptor that interacts with the naturally occurring hormone ghrelin.

Ipamorelin is a synthetic agonist investigated for its ability to interact with this receptor.

Researchers examine its receptor-binding characteristics through biochemical assays, molecular modelling and controlled receptor-signalling experiments.

These studies may investigate ligand affinity, receptor activation and downstream signalling responses.

Growth Hormone Secretagogue Signalling

Growth hormone secretagogues are compounds investigated for their interactions with receptors involved in growth hormone-related signalling systems.

Ipamorelin belongs to a class of synthetic peptides associated with ghrelin-receptor agonism.

Researchers investigate its molecular behaviour through controlled laboratory models examining receptor interactions and signalling mechanisms.

Its receptor profile differs from that of growth-hormone-releasing hormone analogues such as CJC-1295 No DAC, which interact with the GHRH receptor rather than the ghrelin receptor.

These differences make the compounds relevant to comparative research involving distinct peptide receptor pathways.

Receptor Selectivity Research

Ipamorelin has been investigated for its selectivity relative to earlier synthetic growth hormone secretagogues.

Researchers compare its molecular structure and receptor-interaction characteristics with compounds such as GHRP-6.

Experimental investigations may examine receptor affinity, signalling responses and differences in the activity profiles of synthetic peptide agonists.

The results of non-clinical receptor studies should not be interpreted as evidence of therapeutic safety or effectiveness in humans.

Certificate of Analysis

PCH Peptides provides batch-specific analytical documentation for its Ipamorelin research material.

The PCH Peptides COA Library lists one Certificate of Analysis and one endotoxin report for Ipamorelin.

The submitted HPLC purity figure for the 10mg configuration is 99.93%.

Researchers should verify this percentage against the applicable batch Certificate of Analysis before relying on it as a current analytical result.

The COA should be reviewed for compound identity, purity, lot information and available testing findings.

The endotoxin report should be reviewed separately because endotoxin analysis and HPLC purity testing measure different material characteristics.

Batch-specific documentation supports laboratory quality assessment and material traceability.

For further information about research-use classifications and analytical documentation, review the Research Use Only Peptides Guide.

Storage and Handling

Keep the Ipamorelin vial sealed until required for an authorized laboratory workflow.

Store the lyophilized material in a cold, dry environment protected from moisture, excessive heat and direct light, following the temperature recommendations on the product label and applicable batch documentation.

Appropriate storage conditions help maintain the integrity of synthetic peptide research materials during laboratory handling.

Avoid using material from vials with damaged packaging, broken seals or uncertain identification.

Reconstitution Solution is available separately for suitable laboratory research applications.

Researchers seeking general information about handling lyophilized materials can review the educational guide on how peptide reconstitution works.

Related Research Materials

Laboratories investigating ghrelin-receptor activity and growth hormone-related peptide signalling may also examine other synthetic research compounds.

• CJC-1295 No DAC – A modified growth-hormone-releasing hormone analogue investigated in GHRH receptor-binding assays and peptide signalling research.
• CJC-1295 No DAC / Ipamorelin Blend – A combined research formulation containing 10mg CJC-1295 No DAC and 10mg Ipamorelin, providing 20mg total material in one lyophilized vial.
• GHRP-6 Acetate – A synthetic hexapeptide investigated for its interaction with the ghrelin receptor and comparative growth hormone secretagogue research.
• Tesamorelin – A synthetic GHRH analogue investigated in receptor-binding and growth hormone-related molecular signalling models.

Although these compounds are associated with related areas of peptide research, they differ in molecular structure and primary receptor interactions.

Ipamorelin and GHRP-6 are investigated as ghrelin-receptor agonists, while CJC-1295 No DAC and Tesamorelin interact with the GHRH receptor.

These distinctions are relevant to comparative receptor-binding and molecular characterization studies.

Researchers can explore additional compounds through the PCH Peptides research catalog.

Frequently Asked Questions

What is Ipamorelin used for in research?

Ipamorelin is investigated in laboratory studies involving ghrelin-receptor binding, growth hormone secretagogue signalling, peptide stability and receptor selectivity.

Researchers also compare its molecular characteristics with other synthetic secretagogues in controlled biochemical and cellular models.

These experimental applications do not establish therapeutic safety or effectiveness for human use.

What purity is your Ipamorelin?

The submitted batch HPLC purity figure is 99.93%.

This result should be verified against the current Ipamorelin batch Certificate of Analysis before being presented as a confirmed measurement.

The COA Library provides access to available analytical documentation.

How is Ipamorelin different from GHRP-6?

Both Ipamorelin and GHRP-6 interact with the ghrelin receptor (GHS-R1a).

Ipamorelin is a synthetic pentapeptide containing five amino acid residues, while GHRP-6 is a hexapeptide containing six.

Ipamorelin has been investigated for a comparatively selective activity profile in experimental research, while GHRP-6 is an earlier synthetic secretagogue commonly used in receptor-binding studies.

Researchers can review the GHRP-6 Acetate product page for additional information about the related compound.

What receptor does Ipamorelin target?

Ipamorelin primarily interacts with the growth hormone secretagogue receptor, GHS-R1a.

This receptor is also targeted by ghrelin, a naturally occurring peptide hormone.

Researchers study Ipamorelin’s receptor interaction through controlled biochemical and molecular signalling assays.

What is the amino acid sequence of Ipamorelin?

Ipamorelin has the five-residue sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.

Its structure includes non-natural amino acid residues that distinguish it from naturally occurring peptide hormones.

The peptide has an approximate molecular weight of 711.9 g/mol.

Is Ipamorelin available as a blend?

Yes. PCH Peptides lists Ipamorelin individually and as part of the CJC-1295 No DAC / Ipamorelin Blend.

The combined formulation contains 10mg of CJC-1295 No DAC and 10mg of Ipamorelin in one 20mg lyophilized vial.

The two compounds interact with different receptor systems, making the formulation relevant to comparative laboratory research.

What size does Ipamorelin come in?

PCH Peptides supplies Ipamorelin as a 10mg lyophilized research material in a single vial.

The product is intended exclusively for qualified laboratory, academic and institutional research applications.

Is Ipamorelin batch tested?

The PCH Peptides COA Library lists one Certificate of Analysis and one endotoxin report for Ipamorelin.

Researchers should review the applicable batch documentation to verify compound identity, purity and analytical testing results.

Available certificates can be accessed through the COA Library.

How should Ipamorelin be stored?

Ipamorelin should remain sealed and protected from moisture, excessive heat and direct light.

Follow the temperature and handling recommendations printed on the product label and any applicable batch-specific documentation.

Appropriate storage helps maintain the integrity of lyophilized peptide research materials.

Is Ipamorelin intended for human or animal use?

No. Ipamorelin is supplied strictly for laboratory, academic and institutional research.

It is not intended for human or animal consumption, injection, therapeutic applications, diagnosis or veterinary use.

For additional information about research material classifications, read the Research Use Only Peptides Guide.

Do you provide dosage instructions for Ipamorelin?

No. PCH Peptides does not provide dosage, administration or usage protocols. Ipamorelin is supplied exclusively for qualified research use only.